Table 1.
Demographic and clinical data for the 20 representative patients included in the study
| Patient number | Age (years) | F/M | Duration of disease (years) | Source of synovial tissue | CRP (mg/l) | RF | DMARDs | NSAIDs | Corticosteroid |
| Rheumatoid arthritis patients | |||||||||
| 1 | 32 | M | 5 | TJR, knee joint left | 82.7 | + | + | - | + |
| 2 | 49 | F | 6 | Expiration baker cystis, knee joint right | 32.5 | + | + | - | + |
| 3 | 73 | M | 10 | TJR, knee joint right | 74.8 | + | - | + | - |
| 4 | 65 | F | 16 | TJR, thigh joint right | 29.5 | ? | + | + | + |
| 5 | 60 | M | 9 | SE, knee joint right | 84.6 | + | - | + | - |
| 6 | 55 | F | 10 | TJR, knee joint right | 62.2 | - | - | + | - |
| 7 | 57 | F | 10 | TJR, knee joint left | 17.4 | + | - | + | + |
| 8 | 55 | M | 10 | TJR, knee joint left | 49.5 | - | - | + | - |
| 9 | 46 | M | 8 | SE, wrist joint left | 15.9 | + | + | - | - |
| 10 | 49 | F | 12 | SE, wrist joint right | 40.7 | + | + | + | - |
| Osteoarthritis patients | |||||||||
| 1 | 52 | M | 2 | SE, knee joint left | 96.0 | - | - | - | - |
| 2 | 31 | F | 5 | SE, knee joint left | 36.0 | + | - | - | - |
| 3 | 37 | M | 1 | SE, knee joint right | <5.0 | - | - | - | - |
| 4 | 70 | M | 5 | TJR, knee joint right | <5.0 | - | - | + | - |
| 5 | 77 | M | 8 | TJR, knee joint right | <5.0 | - | - | + | - |
| 6 | 62 | F | 16 | TJR, knee joint right | <5.0 | - | - | + | - |
| 7 | 74 | F | 20 | TJR, knee joint left | <5.0 | - | - | + | - |
| 8 | 69 | F | 10 | TJR, knee joint right | 12.2 | ? | - | + | - |
| 9 | 71 | F | 10 | TJR, knee joint left | 15.9 | + | - | + | - |
| 10 | 67 | F | 1.5 | TJR, knee joint left | <5.0 | - | - | + | - |
CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; F/M, female/male; NSAID, nonsteroidal anti-inflammatory drug; RF, rheumatoid factor; SE, synovectomy; TJR, total joint replacement.